Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAT01H in moderate to severe atopic dermatitis
NCT03089229Phase 2Completed
- Sponsor
- Haus Bioceuticals
- Start
- Mar 2017
- Primary completion
- Jun 2017
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HAT01H in atopic dermatitis (AD), sponsored by Haus Bioceuticals. Started Mar 2017; status: completed.
02
Drugs
HAT01H
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03089229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03089229.